Young R Lee1, Pamela D Miller2, Saeed K Alzghari3, Delilah D Blanco4, Jackson D Hager2, Kailey S Kuntz2. 1. Department of Pharmacy Practice, Texas Tech University Health Sciences Center School of Pharmacy, 1718 Pine Street, Abilene, TX, 79601, USA. young.lee@ttuhsc.edu. 2. Department of Pharmacy Practice, Texas Tech University Health Sciences Center School of Pharmacy, 1718 Pine Street, Abilene, TX, 79601, USA. 3. Gulfstream Genomics, LLC, 9301 N Central Expressway STE 335, Dallas, TX, 75231, USA. 4. Tampa General Hospital, 1 Tampa General Circle, Tampa, FL, 33606, USA.
Abstract
BACKGROUND: Critically ill patients display altered pharmacokinetics and pharmacodynamics and are more likely to be infected with more resistant pathogens. Beta-lactam antibiotics exhibit time-dependent pharmacodynamics; therefore, it is postulated that continuous infusion (CI) may optimize these parameters. OBJECTIVE: To perform a systematic review and meta-analysis of the available literature comparing CI versus intermittent bolus (IB) of beta-lactam antibiotics in critically ill adult patients with respiratory infections to determine if clinical benefits exist. METHODS: PubMed, EMBASE, and Web of Science were searched. Thirteen randomized controlled trials were included in the meta-analyses of clinical cure and/or mortality. Four retrospective studies reporting clinical cure and/or mortality, and 11 studies that reported pharmacokinetic/pharmacodynamic parameters were included in the systematic review. RESULTS: The majority of patients in both groups maintained the percentage of time the free drug concentration exceeded the minimum inhibitory concentration (%fT > MIC) targets throughout the treatment, with differences favoring CI being more prevalent when the MIC of the offending pathogen increased. CI of beta-lactam antibiotics in critically ill adult patients with respiratory infections significantly improved clinical cure rates when compared to IB (risk ratio [RR] 1.177; 95% CI 1.065-1.300). No significant differences in mortality rates were seen when patients were treated with either dosing modality (RR 0.845; 95% CI 0.644-1.108). CONCLUSIONS: CI of beta-lactam antibiotics is associated with better cure rates and higher %fT > MIC when administered to critically ill patients with respiratory infections, but may be most beneficial in severely ill patients with more resistant Gram-negative bacterial infections.
BACKGROUND:Critically illpatients display altered pharmacokinetics and pharmacodynamics and are more likely to be infected with more resistant pathogens. Beta-lactam antibiotics exhibit time-dependent pharmacodynamics; therefore, it is postulated that continuous infusion (CI) may optimize these parameters. OBJECTIVE: To perform a systematic review and meta-analysis of the available literature comparing CI versus intermittent bolus (IB) of beta-lactam antibiotics in critically ill adult patients with respiratory infections to determine if clinical benefits exist. METHODS: PubMed, EMBASE, and Web of Science were searched. Thirteen randomized controlled trials were included in the meta-analyses of clinical cure and/or mortality. Four retrospective studies reporting clinical cure and/or mortality, and 11 studies that reported pharmacokinetic/pharmacodynamic parameters were included in the systematic review. RESULTS: The majority of patients in both groups maintained the percentage of time the free drug concentration exceeded the minimum inhibitory concentration (%fT > MIC) targets throughout the treatment, with differences favoring CI being more prevalent when the MIC of the offending pathogen increased. CI of beta-lactam antibiotics in critically ill adult patients with respiratory infections significantly improved clinical cure rates when compared to IB (risk ratio [RR] 1.177; 95% CI 1.065-1.300). No significant differences in mortality rates were seen when patients were treated with either dosing modality (RR 0.845; 95% CI 0.644-1.108). CONCLUSIONS: CI of beta-lactam antibiotics is associated with better cure rates and higher %fT > MIC when administered to critically illpatients with respiratory infections, but may be most beneficial in severely ill patients with more resistant Gram-negative bacterial infections.
Authors: Leonardo Lorente; Alejandro Jiménez; María M Martín; José Luis Iribarren; Juan José Jiménez; María L Mora Journal: Int J Antimicrob Agents Date: 2009-01-15 Impact factor: 5.283
Authors: Jason A Roberts; Carl M J Kirkpatrick; Michael S Roberts; Andrew J Dalley; Jeffrey Lipman Journal: Int J Antimicrob Agents Date: 2009-12-16 Impact factor: 5.283
Authors: Joel M Dulhunty; Jason A Roberts; Joshua S Davis; Steven A R Webb; Rinaldo Bellomo; Charles Gomersall; Charudatt Shirwadkar; Glenn M Eastwood; John Myburgh; David L Paterson; Therese Starr; Sanjoy K Paul; Jeffrey Lipman Journal: Am J Respir Crit Care Med Date: 2015-12-01 Impact factor: 21.405
Authors: Leonardo Lorente; Alejandro Jiménez; Salome Palmero; Juan José Jiménez; José Luís Iribarren; Melitón Santana; María M Martín; Maria L Mora Journal: Clin Ther Date: 2007-11 Impact factor: 3.393
Authors: N Layios; C Visée; V Mistretta; R Denooz; N Maes; J Descy; F Frippiat; S Marchand; N Grégoire Journal: Antimicrob Agents Chemother Date: 2022-01-31 Impact factor: 5.938
Authors: Ute Chiriac; Otto R Frey; Anka C Roehr; Andreas Koeberer; Patrick Gronau; Thomas Fuchs; Jason A Roberts; Alexander Brinkmann Journal: Medicine (Baltimore) Date: 2021-06-04 Impact factor: 1.817
Authors: Jessica R Tait; Hajira Bilal; Kate E Rogers; Yinzhi Lang; Tae-Hwan Kim; Jieqiang Zhou; Steven C Wallis; Jürgen B Bulitta; Carl M J Kirkpatrick; David L Paterson; Jeffrey Lipman; Phillip J Bergen; Jason A Roberts; Roger L Nation; Cornelia B Landersdorfer Journal: Antibiotics (Basel) Date: 2022-01-13